报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长；同时春立医疗持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现 良好增长。 2月27日晚间，北京市春立正达医疗器械股份有限公司(以下简称"春立医疗")发布2025年度业绩快报。 报告期内，公司实现营业总收入10.44亿元，同比增长29.52%；实现归母净利润2.72亿元，同比增长 117.72%。报告期末，公司总资产为36.59亿元，较期初增长5.58%。 ...

北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月27日南向资金增持16.82万股春立医疗（01858.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持15.2万股。近20个交易日中，获南向资金减持的有12天，累计净减持112.97万 股。截至目前，南向资金持有春立医疗（01858.HK）4121.68万股，占公司已发行普通股的43.31%。 ...

最新公告列表 《2025年度业绩快报公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月27日收盘，春立医疗（688236）报收于22.38元，较前一交易日上涨0.72%，最新总市值 为85.84亿元。该股当日开盘22.2元，最高22.54元，最低22.15元，成交额达3596.92万元，换手率为 0.56%。 近日，北京市春立正达医疗器械股份有限公司发布2025年度业绩快报，营业总收入为1,043,768,680.27 元，同比增长29.52%；归属于母公司所有者的净利润为272,124,670.05元，同比增长117.72%。报告期末 总资产为3,659,165,538.06元，较期初增长5.58%；归属于母公司的所有者权益为2,985,050,158.61元，较 期初增长5.86%。业绩增长主要得益于产品集采落地后销量提升、国际化业务拓展以及运营效率优化。 ...

报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长；同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 格隆汇2月27日丨春立医疗(688236.SH)公布2025年度业绩快报，公司实现营业总收入10.44亿元，较上年 同期增长29.52%；实现归属于母公司所有者的净利润2.72亿元，较上年同期增长117.72%。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，春立医疗发布2025年度业绩快报公告称，公司2025年度实现营业总收入 1043768680.27元，同比增长29.52%；归属于母公司所有者的净利润272124670.05元，同比增长 117.72%。 ...

Group 1 - The core viewpoint of the article highlights that Spring Medical reported a significant increase in its 2025 annual performance, with operating revenue reaching approximately 1.044 billion yuan, representing a year-on-year increase of 29.52% [1] - The net profit attributable to shareholders of the listed company was approximately 272 million yuan, showing a substantial year-on-year increase of 117.72% [1] - The basic earnings per share were reported at 0.71 yuan, which is an increase of 115.15% compared to the previous year [1] Group 2 - The article also discusses a notable shift in the AI landscape, indicating that China's AI usage has surpassed that of the United States for the first time, leading to a surge in various sectors within the A-share market [1] - A well-known Wall Street analyst commented on how China's computing power path is overturning traditional perceptions, suggesting a transformative impact on the industry [1]

Performance Summary - Xinyi Solar (00968.HK) reported a revenue of 20.861 billion yuan for 2025, a decrease of 4.8% year-on-year, with a net profit of 844.5 million yuan, down 16.2%, primarily due to a decline in average selling prices of solar glass products [2] - Zhongxin Innovation (03931.HK) expects a net profit of 2.025 billion to 2.193 billion yuan for 2025, an increase of approximately 140% to 160% compared to the previous year, driven by high growth in leading technology products across passenger, commercial, and energy storage sectors [2] - Rongchang Bio (09995.HK) anticipates a revenue of 3.251 billion yuan for 2025, an increase of 89.36% year-on-year, with a net profit of 709 million yuan, turning profitable due to increased sales of Tislelizumab and injection-use Vedolizumab [2] - Xinyi Energy (03868.HK) expects a revenue of 2.453 billion yuan for 2025, a slight increase of 0.53%, with a net profit of 1.011 billion yuan, up 27.79% [2] - Sihang Property (00083.HK) reported a revenue of 5.185 billion HKD for the six months ending December 31, 2025, an increase of 34.54%, while net profit decreased by 15.77% to 1.533 billion HKD [3] - Haohai Biological Technology (06826.HK) expects a revenue of approximately 2.473 billion yuan for 2025, a decrease of 8.33%, with a net profit of about 251 million yuan, down 40.3% [4] - Chunli Medical (01858.HK) anticipates a total revenue of approximately 1.044 billion yuan for 2025, a year-on-year increase of 29.52%, with a net profit of 272 million yuan, up 117.72% [5] - Baosheng International (03813.HK) issued a profit warning, expecting a net profit of approximately 211 million yuan for 2025, a decrease of about 57.1% [6] - Chip Intelligence Holdings (02166.HK) expects a net profit of approximately 140 million to 170 million HKD for 2025, an increase of about 40% to 70%, benefiting from the booming AI technology and increasing market demand [6] - Fengcai Technology (01304.HK) anticipates a total revenue of approximately 774 million yuan for 2025, a year-on-year increase of 28.91%, with a net profit of about 227 million yuan, up 1.92% [6] - Huayou Energy (01251.HK) issued a profit warning, expecting a loss of approximately 100 million to 150 million HKD for the 2025 fiscal year [7] - Zhoneng Group (00131.HK) reported a revenue of 272 million HKD for the six months ending December 31, 2025, an increase of 250.64%, with a net profit of 180 million HKD, turning profitable [8] - Fudan Zhangjiang (01349.HK) expects a revenue of approximately 686 million yuan for 2025, a decrease of 3.33%, with a net loss of approximately 157 million yuan, turning from profit to loss [9] Company News - Bay Area Development (00737.HK) reported that the total toll revenue for January from the Guangzhou-Shenzhen Expressway, Guangzhou-Zhuhai West Line Expressway, and the Shenzhen section of the Yangtze River Expressway was approximately 241 million, 105 million, and 75.169 million yuan, respectively, representing year-on-year growth of 15%, 17%, and 19% [10] - LeCang Logistics (02490.HK) plans to acquire two large container ships [10] - Innovent Biologics (01801) received approval for Jebatuzumab (Pimobendan) in China for the indication of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma [11] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 2.8582 million shares for a total of approximately 99.9973 million HKD, with a repurchase price ranging from 34.92 to 35.04 HKD per share [12] - Geely Automobile (00175.HK) repurchased 3.673 million shares for approximately 59.4327 million HKD, with a repurchase price between 16.1 and 16.3 HKD [13] - Miniso Group (09896.HK) repurchased approximately 0.0526 million shares for about 1.8893 million HKD, with a repurchase price ranging from 35.64 to 36.34 HKD [14] - NetEase Cloud Music (09899.HK) repurchased approximately 0.09715 million shares for about 14.9959 million HKD, with an average repurchase price of 154.36 HKD [14]

报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长;同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 春立医疗(01858)公布2025年度业绩快报，营业总收入约10.44亿元，同比增长29.52%;归属于母公司所有 者的净利润约2.72亿元，同比增长117.72%;基本每股收益0.71元。 公告称，业绩增长主要原因为：随着骨科耗材国家集采常态化推进，公司依托完善的渠道覆盖网络与丰 富的产品体系，产品销量稳步提升，国内业务规模与市场份额持续扩大，推动盈利水平稳步提升。公司 持续推进国际化战略，依托达到国际先进水平的产品技术与质量标準，在国际市场实现了业务的持续拓 展与突破，海外营收稳步提升，为公司整体业绩增长提供重要支撑。 与此同时，公司聚焦精细化运营管理，优化运营效率;通过规模化生产，进一步强化规模效应，整体运 营效率与盈利能力得到显著提升。 ...

格隆汇2月27日丨春立医疗(01858.HK)公告， 2025年度业绩快报，公司实现营业总收入人民币10.4亿 元，较上年同期增长29.52%；实现归属于母公司所有者的净利润人民币2.72亿元，较上年同期增长 117.72%。 报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长；同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 ...

与此同时，公司聚焦精细化运营管理，优化运营效率;通过规模化生产，进一步强化规模效应，整体运 营效率与盈利能力得到显著提升。 智通财经APP讯，春立医疗(01858)公布2025年度业绩快报，营业总收入约10.44亿元，同比增长29.52%; 归属于母公司所有者的净利润约2.72亿元，同比增长117.72%;基本每股收益0.71元。 公告称，业绩增长主要原因为：随着骨科耗材国家集采常态化推进，公司依托完善的渠道覆盖网络与丰 富的产品体系，产品销量稳步提升，国内业务规模与市场份额持续扩大，推动盈利水平稳步提升。公司 持续推进国际化战略，依托达到国际先进水平的产品技术与质量标準，在国际市场实现了业务的持续拓 展与突破，海外营收稳步提升，为公司整体业绩增长提供重要支撑。 报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长;同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 ...